Los Angeles-based Spinogenix, a privately held small molecule drug discovery and development company, is currently testing two clinical candidates in four diseases: SPG302 in amyotrophic lateral ...

I am excited by the prospects of synaptic regeneration in glaucoma and the opportunity to act as a science advisor to Spinogenix as they begin advancing SPG302 for the treatment of glaucoma.” Glaucoma ...

I am excited by the prospects of synaptic regeneration in glaucoma and the opportunity to act as a science advisor to Spinogenix as they begin advancing SPG302 for the treatment of glaucoma.” ...

brings world-leading clinical and research expertise in glaucoma to Spinogenix as the company plans to launch a new program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma.